- $68.12m
- $43.65m
- $0.92m
Brief: Rafael Holdings Inc Files For Stock Shelf Of Upto $250 Million Of Class B Common Stock
Brief: Rafael Pharmaceuticals Crosses Enrollment Of 150 Patients In Pivotal Phase 3 Trial Of Cpi-613 For Relapsed Or Refractory Acute Myeloid Leukemia
NYSE ORDER IMBALANCE 65413.0 SHARES ON SELL SIDE
Brief: Rafael Holdings Reports Q2 Loss Per Share Of $0.50
Brief: Rafael Holdings Inc Recruits Ameet Mallik To Become Company's Chief Executive Officer
Brief: Rafael Holdings - Selling Stockholder May Sell, Resell Or Otherwise Dispose Of Up To 101,844 Shares Of Co's Class B Common Stock
Brief: Lipomedix Announces Manufacturing Agreement With ForDoz For Promitil®
Brief: Rafael Holdings Files For Offering Of Class B Common Stock Of Up To $6.95 Million
Brief: Rafael Holdings Reports First Quarter 2021 Results
Brief: Rafael Pharmaceuticals Receives FDA Fast Track Designation For Cpi-613 For Treatment Of Pancreatic Cancer
Brief: Rafael Holdings Posts Q4 Loss Per Share $0.34
Brief: FDA Grants Rafael Pharmaceuticals Orphan Drug Designation For CPI-613 For Treatment Of Soft Tissue Sarcoma
Brief: Rafael Pharmaceuticals Crosses Midpoint Of Enrollment To First Interim Analysis In Phase 3 Trial Of Cpi-613 For Relapsed Or Refractory Acute Myeloid Leukemia
Brief: Rafael Holdings Reports Q3 Loss Per Share Of $0.14
Brief: Rafael Pharmaceuticals Enrolls More Than 75% Of Patients Needed For Pivotal Phase 3 TrialOf CPI-613 For Patients With Metastatic Pancreatic Cancer
Brief: Rafael Holdings Reports Q2 Loss Per Share Of $0.08
Brief: Rafael Holdings Inc Says On Feb 3, Rafael Pharma Entered Into Line Of Credit Loan Agreement With RP Finance, Llc
Brief: Rafael Pharmaceuticals Crosses Halfway Enrollment Point In Phase 3 Trial Of Cpi-613®️ To Treat Metastatic Pancreatic Cancer
Brief: Rafael Holdings Q1 Loss Per Share $0.10